Free Trial
NASDAQ:CADL

Candel Therapeutics (CADL) Stock Price, News & Analysis

Candel Therapeutics logo
$5.79 -0.03 (-0.52%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$5.78 0.00 (-0.09%)
As of 08/29/2025 07:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Candel Therapeutics Stock (NASDAQ:CADL)

Key Stats

Today's Range
$5.70
$5.92
50-Day Range
$4.67
$7.02
52-Week Range
$3.79
$14.60
Volume
328,811 shs
Average Volume
598,509 shs
Market Capitalization
$317.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$22.00
Consensus Rating
Buy

Company Overview

Candel Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
49th Percentile Overall Score

CADL MarketRank™: 

Candel Therapeutics scored higher than 49% of companies evaluated by MarketBeat, and ranked 589th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Candel Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Candel Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Candel Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Candel Therapeutics are expected to grow in the coming year, from ($1.47) to ($1.15) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Candel Therapeutics is -8.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Candel Therapeutics is -8.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Candel Therapeutics has a P/B Ratio of 3.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Candel Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    17.60% of the float of Candel Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Candel Therapeutics has a short interest ratio ("days to cover") of 7.
  • Change versus previous month

    Short interest in Candel Therapeutics has recently decreased by 1.52%, indicating that investor sentiment is improving.
  • Dividend Yield

    Candel Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Candel Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    17.60% of the float of Candel Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Candel Therapeutics has a short interest ratio ("days to cover") of 7.
  • Change versus previous month

    Short interest in Candel Therapeutics has recently decreased by 1.52%, indicating that investor sentiment is improving.
  • News Sentiment

    Candel Therapeutics has a news sentiment score of 1.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.09 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Candel Therapeutics this week, compared to 3 articles on an average week.
  • Search Interest

    Only 11 people have searched for CADL on MarketBeat in the last 30 days. This is a decrease of -35% compared to the previous 30 days.
  • MarketBeat Follows

    Only 3 people have added Candel Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Candel Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,476.00 in company stock.

  • Percentage Held by Insiders

    16.60% of the stock of Candel Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 13.93% of the stock of Candel Therapeutics is held by institutions.

  • Read more about Candel Therapeutics' insider trading history.
Receive CADL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Candel Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CADL Stock News Headlines

Altucher: It Looks Like My Trump prediction is coming true
New Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Trump’s Great Gain” has officially begun. Altucher believes select cryptos could turn $900 into $108,000 over the next 12 months — and he’s laying out the full gameplan in a new presentation.tc pixel
Candel Therapeutics secures RMAT for prostate cancer – ICYMI
See More Headlines

CADL Stock Analysis - Frequently Asked Questions

Candel Therapeutics' stock was trading at $8.68 at the beginning of 2025. Since then, CADL shares have decreased by 33.3% and is now trading at $5.79.

Candel Therapeutics, Inc. (NASDAQ:CADL) posted its quarterly earnings data on Thursday, August, 14th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.08.

Candel Therapeutics (CADL) raised $72 million in an IPO on Tuesday, July 27th 2021. The company issued 9,000,000 shares at $8.00 per share. Jefferies, Credit Suisse, BMO Capital Markets and UBS Investment Bank served as the underwriters for the IPO.

Candel Therapeutics' top institutional investors include Acorn Capital Advisors LLC (5.15%), Geode Capital Management LLC (1.80%), Halter Ferguson Financial Inc. (1.55%) and Tanager Wealth Management LLP (0.39%). Insiders that own company stock include Paul B Manning, Estuardo Aguilar-Cordova, Paul Peter Tak, Francesca Barone, Seshu Tyagarajan, William Garrett Nichols, Charles Schoch, Jason Amello and Joseph C Papa.
View institutional ownership trends
.

Shares of CADL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Candel Therapeutics investors own include Advanced Micro Devices (AMD), Netflix (NFLX), NVIDIA (NVDA), Tesla (TSLA), Alphabet (GOOG), Meta Platforms (META) and Visa (V).

Company Calendar

Last Earnings
8/14/2025
Today
8/31/2025
Next Earnings (Estimated)
11/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CADL
CIK
1841387
Fax
N/A
Employees
60
Year Founded
N/A

Price Target and Rating

High Price Target
$25.00
Low Price Target
$15.00
Potential Upside/Downside
+280.0%
Consensus Rating
Buy
Rating Score (0-4)
3.20
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.69)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$55.18 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-41.00%
Return on Assets
-26.81%

Debt

Debt-to-Equity Ratio
0.01
Current Ratio
7.04
Quick Ratio
7.04

Sales & Book Value

Annual Sales
$120 thousand
Price / Sales
2,648.93
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.64 per share
Price / Book
3.53

Miscellaneous

Outstanding Shares
54,900,000
Free Float
45,782,000
Market Cap
$317.87 million
Optionable
Optionable
Beta
-0.88

Social Links

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:CADL) was last updated on 8/31/2025 by MarketBeat.com Staff
From Our Partners